Henry Ingersoll Bowditch (1808-82): American physician, public health advocate and social reformer.

J Med Biogr

Department of Neurology, Boston University School of Medicine, 72 East Concord Street, Robinson Building, 5th Floor, Room 528, Boston, MA 02118, USA.

Published: November 2011

Henry Ingersoll Bowditch, a Bostonian physician from the mid-19th century, lived a passionate life full of commitment and devotion to various noble causes--he was a champion of public health, an advocate for inclusion of women in medicine and a staunch abolitionist, all unpopular social perspectives at that time in medical and political history. Seemingly difficult personality traits including his stubbornness and moralistic outlook were likely 'adaptive' as he confronted the political reality of major institutional change. His interest in statistical trends and environmental influences and his inductive reasoning led to a deeper understanding of consumption (tuberculosis), the widespread diagnostic use of the stethoscope and thoracocentesis.

Download full-text PDF

Source
http://dx.doi.org/10.1258/jmb.2010.010027DOI Listing

Publication Analysis

Top Keywords

henry ingersoll
8
ingersoll bowditch
8
public health
8
health advocate
8
bowditch 1808-82
4
1808-82 american
4
american physician
4
physician public
4
advocate social
4
social reformer
4

Similar Publications

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.

N Engl J Med

October 2012

Duke Clinical Research Institute and Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA.

Background: The effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization has not been delineated.

Methods: In this double-blind, randomized trial, in a primary analysis involving 7243 patients under the age of 75 years receiving aspirin, we evaluated up to 30 months of treatment with prasugrel (10 mg daily) versus clopidogrel (75 mg daily). In a secondary analysis involving 2083 patients 75 years of age or older, we evaluated 5 mg of prasugrel versus 75 mg of clopidogrel.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!